Acrivon Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-03-31 was 225.00 shares, a 98.89% decline year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 225.00 shares, a 99.27% decline from fiscal 2024.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 30.88K shares, a 89.44% decline from fiscal 2023.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 292.44K shares, a 1067.95% increase from fiscal 2022.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 25.04K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 225.00 shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 225.00 shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 225.00 shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | 225.00 shares 10-Q · filed 2025-05-14 | 10.82K shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 30.88K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 139.39K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 10.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 175.06K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 20.28K shares 10-Q · filed 2024-05-14 | 312.49K shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 108.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 292.44K shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 35.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -1.94M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 148.03K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | |
| 2023-03-31 | 232.00 shares 10-Q · filed 2023-05-09 | |
| 2022-12-31 | -2.12M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | 25.04K shares 10-K · filed 2023-03-28 |
| 2021-12-31 | 881.61K shares 10-Q · filed 2022-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |